Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.
Tennessee Oncology, Nashville, Tennessee, United States
Florida Cancer Specialists, Fort Myers, Florida, United States
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal ph, Saint Petersburg, Russian Federation
Hôpital LARIBOISIERE, Paris, France
City of Hope Comprehensive Cancer Center, Duarte, California, United States
Stanford University School of Medicine, Stanford, California, United States
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.